News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelGenx Corp. Announces Commencement of Pivotal Clinical Trial for Anti-Migraine VersaFilm


4/24/2012 9:57:31 AM

SAINT LAURENT, Quebec, April 24, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced the commencement of a pivotal bioequivalence clinical trial with its anti-migraine VersaFilm product, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. The screening and recruitment of all subjects for the trial has been completed, and first dosing commenced on April 23, 2012.

Read at GlobeNewswire


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES